Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response
Top Cited Papers
Open Access
- 1 July 2015
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 1 (4), 466-474
- https://doi.org/10.1001/jamaoncol.2015.1313
Abstract
High-throughput next-generation sequencing has provided enormous insight into the genomic landscape of several tumor types, illuminating molecularly defined tumor subtypes, identifying new druggable targets, and providing insights into the heterogeneity of many tumors.1 Metastatic tumors often undergo genomic evolution during progression and resistance, and therefore genomic drivers may not always be evident in the primary tumor. Furthermore, no specific guidelines exist to help clinicians interpret and contextualize individual patients’ genomic information when making therapeutic decisions. Herein, we describe an evidence-based precision medicine trial for patients with metastatic or treatment-resistant disease using a whole-exome sequencing (WES) clinical test called EXaCT-1, developed and validated by our group. Unique aspects include analysis of more than 21 000 genes of the cancer exome rather than a targeted hot-spot gene approach, complete disclosure of results through a WES clinical report, incorporation of metastatic and serial biopsies, use of fresh/frozen and formalin-fixed tissue, and development of patient-derived organoids and xenografts for co-clinical trials. Integral to the study are a comprehensive computational pipeline capable of categorizing mutations and generating a report for discussion in a multidisciplinary precision medicine tumor board and clinical follow-up to determine the clinical impact of mutations on subsequent response to therapies and patient outcomes. The overarching goals of our trial are to understand how WES affects therapeutic decision making in the context of advanced cancer care and to identify novel biomarkers of response.Keywords
This publication has 13 references indexed in Scilit:
- Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled AnalysisJournal of Clinical Oncology, 2014
- Organoid Cultures Derived from Patients with Advanced Prostate CancerCell, 2014
- Unraveling the clonal hierarchy of somatic genomic aberrationsGenome Biology, 2014
- High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug DevelopmentCancer Research, 2014
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate CancerClinical Cancer Research, 2013
- Lessons from the Cancer GenomeCell, 2013
- Fanconi anaemia and the repair of Watson and Crick DNA crosslinksNature, 2013
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC TrialJournal of Clinical Oncology, 2009
- Androgen-Independent Prostate Cancer Is a Heterogeneous Group of DiseasesCancer Research, 2004
- Heterogeneous spectrum of mutations in the Fanconi anaemia group A geneEuropean Journal of Human Genetics, 1999